Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week Untangles The String Of Pearls

Executive Summary

In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.


Related Content

With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Gilead Is First Splash In HIV Patent Pool; Five Other Firms In Negotiations
AstraZeneca Opts Out Of Targacept Schizophrenia Program
With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
AstraZeneca Drops Targacept's Failed ADHD Drug
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
What Medarex Has To Offer At $2.4 Billion
Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts